Madrigal Stock Analysis

MDGL
 Stock
  

USD 68.81  3.47  5.31%   

The small pull down in market price for the last few months may encourage stakeholders to take a closer look at the firm as it is trading at a share price of 68.81 on very low momentum in trading volume. The company directors and management did not add much value to Madrigal Pharmaceuticals investors in October. However, diversifying your holdings with Madrigal Pharmaceuticals or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.28. This high volatility is attributed to the latest market swings and not-so-good earnings reports for some of the Madrigal Pharmaceuticals partners.
Additionally, see Correlation Analysis.
  
The Madrigal Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Madrigal Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Madrigal Stock analysis module also helps to analyze the Madrigal Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Madrigal Stock Analysis Notes

About 19.0% of the company outstanding shares are owned by corporate insiders. The book value of Madrigal Pharmaceuticals was now reported as 15.47. The company recorded a loss per share of 13.09. Madrigal Pharmaceuticals last dividend was issued on the 30th of September 2010. The entity had 1:35 split on the 25th of July 2016. Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania. Madrigal Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 71 people. To find out more about Madrigal Pharmaceuticals contact Chen Schor at 267 824-2827 or learn more at www.madrigalpharma.com.

Madrigal Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Madrigal Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Madrigal Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Madrigal Pharmaceuticals generated a negative expected return over the last 90 days
Madrigal Pharmaceuticals has high historical volatility and very poor performance
The company reported the previous year's revenue of 147 K. Net Loss for the year was (255.9 M) with profit before overhead, payroll, taxes, and interest of 10.31 M.
Madrigal Pharmaceuticals currently holds about 211.77 M in cash with (200.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.38.
Madrigal Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Over 80.0% of the company shares are owned by institutional investors

Madrigal Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Madrigal Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Madrigal Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Madrigal Largest EPS Surprises

Earnings surprises can significantly impact Madrigal Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2017-08-10
2017-06-30-0.6-0.69-0.0915 
2017-11-09
2017-09-30-0.79-0.680.1113 
2018-08-07
2018-06-30-0.63-0.450.1828 
View All Earnings Estimates

Madrigal Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Madrigal Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Madrigal Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Madrigal Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
4th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
17th of June 2022
Submission of Matters to a Vote of Security Holders
View
19th of May 2022
Unclassified Corporate Event
View
9th of May 2022
Financial Statements and Exhibits. Unregistered Sales of Equity Securities. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Results of Operations and Financial Condition. Entry into a Material Definitive Agreement
View
24th of February 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
14th of February 2022
Unclassified Corporate Event
View
11th of February 2022
Unclassified Corporate Event
View
10th of February 2022
Unclassified Corporate Event
View

Madrigal Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Madrigal Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Madrigal Pharmaceuticals backward and forwards among themselves. Madrigal Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Madrigal Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Zurcher Kantonalbank Zurich CantonalbankCommon Shares1.6 K114 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares1.6 K160 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares1.3 K107 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares1.3 K100 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares1.3 K123 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares1.3 K147 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares1.3 K140 K
Note, although Madrigal Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Madrigal Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 1.18 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Madrigal Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Madrigal Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Madrigal Profitablity

Madrigal Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Madrigal Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Madrigal Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Madrigal Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Madrigal Pharmaceuticals' profitability requires more research than a typical breakdown of Madrigal Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Investment(92.26) (99.55) 
Return on Average Assets(86.32) (93.14) 
Return on Average Equity(110.92) (119.67) 
Return on Invested Capital(1.20) (1.30) 
Return on Sales(373.11) (382.93) 

Management Efficiency

The entity has return on total asset (ROA) of (58.7) % which means that it has lost $58.7 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (144.5) %, meaning that it created substantial loss on money invested by shareholders. Madrigal Pharmaceuticals management efficiency ratios could be used to measure how well madrigal pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Investment is estimated to pull down to -99.55. The value of Return on Average Assets is estimated to pull down to -93.14. Madrigal Pharmaceuticals Revenue to Assets are relatively stable at the moment as compared to the past year. The company's current value of Revenue to Assets is estimated at 0.001684. Total Assets Per Share is expected to hike to 24.21 this year, although the value of Current Assets will most likely fall to nearly 219.1 M.
Last ReportedProjected for 2022
Book Value per Share 11.86  12.79 
Enterprise Value over EBIT(6.00) (6.47) 
Enterprise Value over EBITDA(5.80) (6.26) 
Price to Book Value 7.39  6.43 
Tangible Assets Book Value per Share 16.53  20.08 
Enterprise Value1.4 B1.2 B
Tangible Asset Value273.3 M252.4 M

Technical Drivers

As of the 30th of November, Madrigal Pharmaceuticals secures the Risk Adjusted Performance of 0.0276, mean deviation of 3.32, and Downside Deviation of 4.0. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Madrigal Pharmaceuticals, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Madrigal Pharmaceuticals, which can be compared to its peers in the industry. Please verify Madrigal Pharmaceuticals treynor ratio, and the relationship between the standard deviation and downside variance to decide if Madrigal Pharmaceuticals is priced some-what accurately, providing market reflects its recent price of 68.81 per share. Given that Madrigal Pharmaceuticals has jensen alpha of (0.026072), we recommend you to check Madrigal Pharmaceuticals's last-minute market performance to make sure the company can sustain itself at a future point.

Madrigal Pharmaceuticals Price Movement Analysis

The output start index for this execution was thirty-two with a total number of output elements of twenty-nine. The MESA Adaptive Moving Average indicator adapts to Madrigal Pharmaceuticals price movement based on the rate change of phase as measured by the Hilbert Transform Discriminator.
.

Madrigal Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Madrigal Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Madrigal Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Madrigal Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Singh Amar over a month ago via Macroaxis 
Payment of 69 shares by Singh Amar of Madrigal Pharmaceuticals subject to Rule 16b-3
Lynch Brian Joseph over three months ago via Macroaxis 
Acquisition by Lynch Brian Joseph of 25000 shares of Madrigal Pharmaceuticals subject to Rule 16b-3
Rebecca Taub over three months ago via Macroaxis 
Acquisition by Rebecca Taub of 61500 shares of Madrigal Pharmaceuticals subject to Rule 16b-3
James Daly over three months ago via Macroaxis 
Acquisition by James Daly of 9470 shares of Madrigal Pharmaceuticals subject to Rule 16b-3
Waltermire Robert E over six months ago via Macroaxis 
Acquisition by Waltermire Robert E of 12250 shares of Madrigal Pharmaceuticals subject to Rule 16b-3
Craves Fred B over six months ago via Macroaxis 
Madrigal Pharmaceuticals exotic insider transaction detected
Bay City Capital Llc over six months ago via Macroaxis 
Acquisition or disposition of Madrigal Pharmaceuticals securities by Bay City Capital Llc
Howarth Alex G over a year ago via Macroaxis 
Acquisition by Howarth Alex G of 5000 shares of Madrigal Pharmaceuticals subject to Rule 16b-3
Waltermire Robert E over a year ago via Macroaxis 
Acquisition by Waltermire Robert E of 35000 shares of Madrigal Pharmaceuticals subject to Rule 16b-3
David Milligan over a year ago via Macroaxis 
Exercise or conversion by David Milligan of 10000 shares of Madrigal Pharmaceuticals subject to Rule 16b-3
James Daly over a year ago via Macroaxis 
Acquisition by James Daly of 12489 shares of Madrigal Pharmaceuticals subject to Rule 16b-3
Howarth Alex G over a year ago via Macroaxis 
Acquisition by Howarth Alex G of 65000 shares of Madrigal Pharmaceuticals subject to Rule 16b-3

Madrigal Pharmaceuticals Technical and Predictive Indicators

Madrigal Pharmaceuticals Forecast Models

Madrigal Pharmaceuticals time-series forecasting models is one of many Madrigal Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Madrigal Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Madrigal Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Madrigal Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Madrigal shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Madrigal Pharmaceuticals. By using and applying Madrigal Stock analysis, traders can create a robust methodology for identifying Madrigal entry and exit points for their positions.
Last ReportedProjected for 2022
Gross Margin 0.90  0.89 

Current Madrigal Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Madrigal analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Madrigal analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
167.57Buy7Odds
Madrigal Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Madrigal analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Madrigal stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Madrigal Pharmaceuticals, talking to its executives and customers, or listening to Madrigal conference calls.
Madrigal Analyst Advice Details

Madrigal Stock Analysis Indicators

Madrigal Pharmaceuticals stock analysis indicators help investors evaluate how Madrigal Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Madrigal Pharmaceuticals shares will generate the highest return on investment. By understating and applying Madrigal Pharmaceuticals stock analysis, traders can identify Madrigal Pharmaceuticals position entry and exit signals to maximize returns.
Quick Ratio2.52
Fifty Two Week Low52.33
Shares Short Prior Month1.49M
Average Daily Volume Last 10 Day264.6k
Average Daily Volume In Three Month267.27k
Shares Percent Shares Out9.06%
Short Percent Of Float11.11%
Forward Price Earnings-4.54
Float Shares7.42M
Fifty Two Week High105.93
Enterprise Value To Ebitda-4.15
Fifty Day Average68.22
Two Hundred Day Average74.75
Additionally, see Correlation Analysis. Note that the Madrigal Pharmaceuticals information on this page should be used as a complementary analysis to other Madrigal Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Complementary Tools for Madrigal Stock analysis

When running Madrigal Pharmaceuticals price analysis, check to measure Madrigal Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Madrigal Pharmaceuticals is operating at the current time. Most of Madrigal Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Madrigal Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Madrigal Pharmaceuticals' price. Additionally, you may evaluate how the addition of Madrigal Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Is Madrigal Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
1.1 B
Return On Assets
(0.74) 
Return On Equity
(2.23) 
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Madrigal Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.